It may be recommendable that m6A modulators associated with anticancer immune components and activities be selected and form the basis for further drug development; particularly, those with clear and obvious interactions with famous cancer immune markers whose functions have been well revealed (e.g., PD-1/L1, CTLA4, and CD47) should be the focus. The gene discussed is CD47; the disease is cancer.